BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon. I will be your conference operator today. All lines have been placed on mute to prevent any background noise. After the company's remarks, there will be a question and answer session. Before we begin, I would like to remind everyone that today's call may contain forward looking statements within the meaning of the federal securities laws, including, but not limited to, statements about BridgeBio's future operating and financial performance, business plans and prospects and strategy. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied in these forward looking statements. For a discussion of these risks and uncertainties, please refer to the disclosure in today's earnings release and BridgeBio's periodic reports and SEC filings. All statements made here are based on information available to BridgeBio as of today, and the company undertakes no obligation to update any forward looking statements made during this call, except as required by law. With that completed, BridgeBio, you may begin your conference. Good afternoon, everyone, and thank you for joining BridgeBio Pharma's second quarter twenty twenty six earnings call. I'm Chinmay Shukla, senior vice president, strategic finance. With me today are Neil Kumar, our CEO, who'll walk through our commercial pipeline and business updates Matt Outen, our chief commercial officer, who'll provide additional detail on our TruBio and our launch readiness and Tom Tremarkey, our president and CFO, who will review our financial results. During today's call, we will cover another quarter of consistent growth for Atruby, along with new data reinforcing its clinical differen...